• John P Bilezikian, Leonardo Bandeira, Aliya Khan, and Natalie E Cusano.
• Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: jpb2@columbia.edu.
• Lancet. 2018 Jan 13; 391 (10116): 168-178.

AbstractPrimary hyperparathyroidism is a common endocrine disorder of calcium metabolism characterised by hypercalcaemia and elevated or inappropriately normal concentrations of parathyroid hormone. Almost always, primary hyperparathyroidism is due to a benign overgrowth of parathyroid tissue either as a single gland (80% of cases) or as a multiple gland disorder (15-20% of cases). Primary hyperparathyroidism is generally discovered when asymptomatic but the disease always has the potential to become symptomatic, resulting in bone loss and kidney stones. In countries where biochemical screening tests are not common, symptomatic primary hyperparathyroidism tends to predominate. Another variant of primary hyperparathyroidism has been described in which the serum calcium concentration is within normal range but parathyroid hormone is elevated in the absence of any obvious cause. Primary hyperparathyroidism can be cured by removal of the parathyroid gland or glands but identification of patients who are best advised to have surgery requires consideration of the guidelines that are regularly updated. Recommendations for patients who do not undergo parathyroid surgery include monitoring of serum calcium concentrations and bone density.Copyright © 2018 Elsevier Ltd. All rights reserved.

6 keywords...

hide…